Agilent Technologies (NYSE:A) had its price target hoisted by Cowen from $80.00 to $90.00 in a report released on Tuesday, The Fly reports. Cowen currently has an outperform rating on the medical research company’s stock.

Other research analysts also recently issued reports about the stock. Needham & Company LLC reaffirmed a buy rating and issued a $88.00 price objective (up from $77.00) on shares of Agilent Technologies in a report on Monday, February 25th. Zacks Investment Research raised shares of Agilent Technologies from a hold rating to a buy rating and set a $88.00 price objective for the company in a report on Friday, February 22nd. Janney Montgomery Scott reiterated a buy rating and issued a $90.00 target price (up from $80.00) on shares of Agilent Technologies in a research note on Thursday, February 21st. Bank of America reiterated a buy rating and issued a $87.00 target price (up from $78.00) on shares of Agilent Technologies in a research note on Thursday, February 21st. Finally, Deutsche Bank reiterated a buy rating and issued a $90.00 target price on shares of Agilent Technologies in a research note on Thursday, February 21st. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $87.17.

A opened at $79.70 on Tuesday. The company has a market capitalization of $25.61 billion, a P/E ratio of 28.57, a price-to-earnings-growth ratio of 2.24 and a beta of 1.38. Agilent Technologies has a 12 month low of $60.42 and a 12 month high of $82.27. The company has a quick ratio of 2.79, a current ratio of 3.39 and a debt-to-equity ratio of 0.36.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, February 20th. The medical research company reported $0.76 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.03. The company had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.27 billion. Agilent Technologies had a net margin of 22.86% and a return on equity of 19.90%. Agilent Technologies’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same period last year, the firm earned $0.66 EPS. On average, equities analysts expect that Agilent Technologies will post 3.06 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 24th. Shareholders of record on Tuesday, April 2nd will be paid a $0.164 dividend. This represents a $0.66 annualized dividend and a yield of 0.82%. The ex-dividend date of this dividend is Monday, April 1st. Agilent Technologies’s dividend payout ratio is presently 23.66%.

In other news, SVP Michael Tang sold 6,728 shares of the firm’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $80.50, for a total transaction of $541,604.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Michael R. Mcmullen sold 17,491 shares of the firm’s stock in a transaction on Wednesday, January 30th. The shares were sold at an average price of $75.00, for a total transaction of $1,311,825.00. Following the sale, the chief executive officer now owns 456,430 shares in the company, valued at approximately $34,232,250. The disclosure for this sale can be found here. Insiders sold a total of 83,722 shares of company stock worth $6,532,504 over the last quarter.

Several institutional investors have recently bought and sold shares of the company. Machina Capital S.A.S. purchased a new stake in shares of Agilent Technologies during the 4th quarter valued at $457,000. Norges Bank bought a new position in shares of Agilent Technologies during the 4th quarter valued at $200,642,000. Massmutual Trust Co. FSB ADV grew its holdings in shares of Agilent Technologies by 22.3% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 2,817 shares of the medical research company’s stock valued at $190,000 after purchasing an additional 513 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund bought a new position in shares of Agilent Technologies during the 4th quarter valued at $425,000. Finally, WealthTrust Fairport LLC grew its holdings in shares of Agilent Technologies by 1.1% during the 4th quarter. WealthTrust Fairport LLC now owns 111,082 shares of the medical research company’s stock valued at $7,494,000 after purchasing an additional 1,238 shares during the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Featured Article: How accurate is the Rule of 72?

The Fly

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.